EN
CN EN
About Accropeutics
Accropeutics is dedicated to the discovery and development of innovativedrugs for inflammation, autoimmune diseases and cancer.
Accropeutics focuses on the "Cell Death - Inflammation" loop and has established a unique "Regulated Cell Death" drug discovery platform. Accropeutic’s R&D team has broad experience from target validation to clinical development, and efficiently progressed a number of First in Class/Best in Class assets into clinical development.
Learn More
Focus Areas
The core R&D team is made of industrial and academic experts in Regulated Cell Death, drug discovery and development.
Learn More
News
Accropeutics doses TYK2/JAK1 inhibitor AC-201 in Psoriasis Patient in China

Suzhou, China, May 6th, 2024——Accro Bioscience (Suzhou) Limited (Accropeutics) announced today that the first psoriasis patient has been dosed in the phase 2 clinical trial of the TYK2/JAK1 inhibitor AC-201 in China. This study is a multicenter, randomized, double-blind, parallel group, placebo-controlled phase II clinical trial to evaluate the efficacy, safety, and pharmacokinetic characteristics of AC-201 in subjects with moderate to severe plaque psoriasis.
Accropeutics Bioscience Announces Positive Results from its Phase I Clinical Trial Evaluating RIPK2 Kinase Inhibitor AC-101 in Healthy Human Subjects in Australia

Suzhou China, April 26, 2024 - Accro Bioscience (Suzhou) Limited (Accropeutics), a clinical-stage biotech company with a focus on molecular mechanisms of regulated cell death and related pathogenesis in human diseases, today announces positive results at the completion of the Phase I study of its drug candidate AC-101 in healthy human subjects. The Phase I trial was a single center, randomized, double-blind, placebo-controlled, single and multiple ascending dose study following oral administration in healthy human subjects, to evaluate the safety, tolerability, pharmacokinetics and the effects of food of AC-101.
Accropeutics’s RIPK1 inhibitor AC-003 capsule has been granted Orphan Drug Designation by the FDA

Suzhou China, December 25, 2023 —— Accro Bioscience (Suzhou) Limited (Accropeutics) announced that its RIPK1 inhibitor AC-003 capsules for the treatment of acute Graft-versus-Host Disease (aGvHD) has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA).
Selective TYK2/JAK1 Inhibitor AC-201 gained National Medical Products Administration (NMPA) permission for Phase 1

Suzhou China, September 8, 2023 —— Accro Bioscience (Suzhou) Limited (Accropeutics) announced today that its oral small-molecule TYK2/JAK1 inhibitor AC-201 has been approved by the National Medical Products Administration (NMPA) to launch clinical phase 1 trial in China. AC-201 was approved for clinical trials by HREC in Australia in May 2023, and the Phase 1 clinical trial in Australia is currently underway.
RIPK2 Inhibitor AC-101 has been approved by the National Medical Products Administration (NMPA) to conduct clinical trials for Healthy Human Subjects

Suzhou China, June 21, 2023 —— Accropeutics Bioscience announced today that its oral small-molecule RIPK2 inhibitor AC-101 has been approved by the National Medical Products Administration (NMPA) to launch clinical phase I trial in China. The design is a randomized, double-blind, placebo-controlled, single dose, and multiple dose incremental phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and food effects of AC-101 in healthy adults. This is the forth clinical approval obtained by Accropeutics Bioscience this year.
All News
Follow the latest happenings in Accropeutics.
Accropeutics’ R&D team has broad experience from target validation to clinical development.
Contact Us

Copyright 2020.Accro Bioscience(Suzhou)Limited 苏ICP备20039637号